


# ONCOTRAP: Assessing drug response and metastatic potential of patients' renal carcinoma on a chip

Beatrice Cesana<sup>1\*</sup>, Catherine Pillet<sup>1</sup>, Elisa Lambert<sup>1</sup>, Jean-Luc Descotes<sup>2</sup>, Elisa Migliorini<sup>1</sup>, Claude Cochet<sup>1</sup>, Odile Filhol<sup>1</sup>

<sup>1</sup> Univ. Grenoble-Alpes, INSERM 1292, CEA, UMR Biosanté, Grenoble, 38000, France - <sup>2</sup> Centre hospitalier universitaire Grenoble Alpes, CS 10217, 38043 Grenoble, France  
\* beatrice.cesana@cea.fr

## INTRODUCTION

### Tumor microenvironment Niche microenvironment




- clear cell Renal Cell Carcinoma (ccRCC) → most prevalent
- RCC **metastasis** (mRCC) can develop in Lung, Liver and **Bone** → highly heterogeneous + poor treatment response rate
- Our goal → develop a microfluidic chip that evaluate :
  - the **invasiveness** of renal cancer cells in a 3D context
  - their **intravasation** potential.


Inserted into a chip named ONCOTRAP, **tumoroids** formed from the primary tumor of patient can provide a robust preclinical test to study metastatic process.

## METHODS


### SPHEROID MODEL



### INVASION ASSAY



### ATTRACTIVITY ASSAY




## CONCLUSION

- Proof of concept of this device → Spheroids (cell lines)
- Final Aim → Introducing patient-derived tumoroids
- **Final Use**
  - Evaluate **invasiveness** of renal cancer cells and the **metastatic capacities** of a patient's tumor
  - Evaluate **drug response**
  - Creating **personalized medicine**



## RESULTS

### HYDROGEL CHOICE


Spheroid included in a 3D environment = study the **invasive capacities** of cells  
→ Hydrogel choice for ccRCC tumor = **COLLAGEN I**



### INVASION ASSAY – day 7



### ATTRACTIVITY ASSAY



## APPLICATION : AKITA MICROFLUIDIC CHIP

